Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

H.C. Wainwright Upgrades Arcus Biosciences (RCUS) to Buy

February 26, 2025 6:06 AM EST

H.C. Wainwright analyst Emily Bodnar upgraded Arcus Biosciences (NYSE: RCUS) from Neutral to Buy with a price target of $24.00.

The analyst comments "Initial cas + cabo data expected in mid-2025; we are increasingly positive on opportunity given cas efficacy vs belzutifan. The ARC-20 study evaluating casdatifan (cas) monotherapy and in combo with other agents in clear cell renal cell carcinoma (ccRCC) has enrolled ~40 patients in the cas + cabozantinib (cabo) cohort, which is meant to evaluate the same combo and patient population as the Phase 3 PEAK-1 study expected to initiate in 2Q25... More